Publications

Pediatric Exclusivity-Associated Revenues and Labeling Changes, 2013 to 2023.

J Pediatr
Liu ITT, Raymakers AJN, Sarpatwari A, Kesselheim AS.

State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar.

JAMA Health Forum
Kwon Y, Sarpatwari A, Dusetzina SB.

Expansion of 340B Disproportionate Share Hospitals in the United States From 2010 to 2022.

Health Serv Res
Liu BY, Russo M, Kesselheim AS, Knox R, Sarpatwari A, Feldman WB.

Physician Experiences With and Perspectives on Clozapine Prescribing.

JAMA Netw Open
Sarpatwari A, Lu Z, Russo M, Zakoul H, Lee SB, Toyserkani GA, Zhou EH, LaCivita C, Hyatt Hawkins Shaw K, Dal Pan GJ, Kesselheim AS.

Pediatric Exclusivity Revenues for Cancer Drugs.

JAMA Pediatr
Sarpatwari A, Bendicksen L, Hawkins DS, Gore L, Bourgeois FT.

Biosimilar approval pathways: comparing the roles of five medicines regulators.

J Law Biosci
Knox RP, Desai V, Sarpatwari A

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020.

Drug Saf
Mahesri M, Sarpatwari A, Huybrechts KF, Lii J, Lee SB, Toyserkani GA, LaCivita C, Zhou EH, Dal Pan GJ, Kesselheim AS, Bykov K.

Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.

Pediatr Blood Cancer
Liu ITT, Wang J, Sarpatwari A, Kesselheim AS, Feldman WB.

Biosimilar Uptake In The US: Patient And Prescriber Factors.

Health Aff (Millwood)
Hong D, Kesselheim AS, Sarpatwari A, Rome BN

Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.

JAMA Netw Open
Feldman WB, Mahesri M, Sarpatwari A, Huybrechts KF, Zhu Y, Hwang CS, Lii J, Lee SB, Kattinakere Sreedhara S, Toyserkani GA, Zhou EH, Zendel L, LaCivita C, Manzo C, Dal Pan GJ, Kesselheim AS, Bykov K

Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.

JAMA Intern Med
Horrow C, Gabriele SME, Tu SS, Sarpatwari A, Kesselheim AS.

Federal Trade Commission Actions on Prescription Drugs, 2000-2022.

JAMA
Daval CJR, Egilman AC, Sarpatwari A, Kesselheim AS.

How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.

Clin Pharmacol Ther
Sarpatwari A, Lu Z, Russo M, Zakoul H, Lee SB, Toyserkani GA, Zhou EH, LaCivita C, Shaw KHH, Zendel L, Dal Pan GJ, Kesselheim AS.

Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.

Ann Intern Med
Egilman AC, Kesselheim AS, Sarpatwari A, Rome BN.

Use of Artificial Intelligence in Drug Development.

JAMA Netw Open
Druedahl LC, Price WN, Minssen T, Sarpatwari A.

Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.

JAMA
Sarpatwari A, Kohli S, Tu SS, Kesselheim AS.

Independent Advice on Drug Approvals: an Investigation of EMA Practices.

J Gen Intern Med
Daval CJR, Kesselheim AS, Sharpless L, Sarpatwari A.

Improving Drug Supply Chain Security.

JAMA Health Forum
Kannarkat JT, Denham MW, Sarpatwari A.

Outcomes of the 340B Drug Pricing Program: A Scoping Review.

JAMA Health Forum
Knox RP, Wang J, Feldman WB, Kesselheim AS, Sarpatwari A.

Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis.

Ann Intern Med
Hwang CS, Kesselheim AS, Sarpatwari A, Huybrechts KF, Brill G, Rome BN.